Groprinosin pills 500mg N30
Condition: New product
985 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Inosine pranobex
Release form
Pills
Composition
Active ingredient: Inosine pranobex Auxiliary substances: potato starch 85 mg, Polyvinylpyrrolidone 45 mg, Magnesium stearate 10 mg. Active ingredient concentration (mg): 500 mg
Pharmacological effect
Immunostimulating drug with antiviral action. It is a complex containing inosine and a salt of 4-acetamido-benzoic acid with N, N-dimethylamino-2-propanol in a molar ratio of 1: 3. The effectiveness of the complex is determined by the presence of inosine, the second component increases its availability for lymphocytes. Groprinosin blocks the reproduction of viral particles by damaging the genetic apparatus, stimulates macrophage activity, lymphocyte proliferation and the formation of cytokines. Reduces the clinical manifestations of viral diseases, speeds up recovery, increases resistance of the body. virus Herpes simplex, there is a faster healing of the affected surface than in the treatment of tr -traditional way. Less frequently, new vesicles, edema, erosion, and relapse of the disease occur. With the timely use of the drug reduces the incidence of viral infections, reduced the duration and severity of the disease.
Pharmacokinetics
AbsorptionAfter ingestion, the drug is rapidly and almost completely (> 90%) absorbed and has good bioavailability. When taken orally at a dose of 1500 mg Cmax of inosine pranobex is reached after 1 hour and is 600 μg / ml. Not detected in the blood 2 hours after administration. Distribution and metabolism Inosine pranobex consists of inosine and the salt of p-acetamido benzoic acid with N, N-dimethylamino-2-propanol. Each of the components of inosine pranobex is rapidly metabolized. Almost 100% of metabolites are found in the urine in the range of 8 to 24 hours from the time of admission. Inosine is metabolized according to a cycle typical of purine nucleotides, with the formation of uric acid, the concentration of which in the blood serum may increase. As a result, uric acid crystals may form in the urinary tract.Increasing the concentration of uric acid is non-linear in nature and may change by ± 10% within 1-3 hours after ingestion. As a result of the metabolism of p-acetamido-benzoic acid, o-acyl glucuronide is formed; N, N-dimethylamino-2-propanol is metabolized to N-oxide. AUC of p-acetamidobenzoic acid> 88%, AUC N, N - dimethylamino-2-propanol> 77%. Cumulation of the drug in the body is not detected. Excretion of inosine and its metabolites are excreted in the urine. When an equilibrium concentration is reached when taking a daily dose of 4 g, the daily urinary excretion of p-acetamido benzoic acid and its metabolite is approximately 85% of the dose taken; T1 / 2 - 50 min. T1 / 2 N, N-dimethylamino-2-propanol - 3-5 hours. The complete elimination of inosine pranobex and its metabolites from the body occurs within 48 hours.
Indications
immunodeficiency caused by viral infections in patients with normal and weakened immune systems / including Herpes simplex diseases (type Guy type II, genital herpes and herpes other localization); subacute sclerosing panencephalitis
Contraindications
gouty hypertrophagia hypertrophicity and childhood in children up to 2 years of pregnancy and lactation
Precautionary measures
Precautions should be prescribed the drug with xanthine oxidase inhibitors, diuretics, zidovudine, with acute liver failure.
Use during pregnancy and lactation
The drug is contraindicated during pregnancy and lactation (breastfeeding), because its safety in this category of patients has not been established.
Dosage and administration
The drug is administered orally at regular intervals (8 or 6 hours) 3-4 times a day. Tablets are taken after meals with a small amount of water. If the doctor does not prescribe otherwise, they usually take: adults: 6 to 8 pills per day, divided into 3 - 4 doses; children: from 2 to 12 years: 50 mg / kg of weight body per day, divided into 3 - 4 doses; equally, in both adults and children, in severe infectious diseases, the dose can be increased individually under medical supervision to 100 mg / kg body weight per day, divided into 4 - 6 receptions. The drug is usually used for 5 days, sometimes longer, depending on the course of the disease.After an 8-day break, the course of treatment can be repeated.
Side effects
In the initial period of treatment may decrease appetite, nausea, vomiting, diarrhea; a slight increase in the concentration of uric acid in the blood and urine; allergic reactions.
Overdose
In case of overdose, gastric lavage and symptomatic therapy are indicated.
Interaction with other drugs
Immunosuppressants weaken the immunostimulating effect of the drug Groprinosin. Groprinosin should be used with caution in patients taking both xanthine oxidase inhibitors (allopurinol) or loop diuretics (furosemide, Torsemide, ethacrynic acid), because this can lead to an increase in serum uric acid concentration. The combined use of the drug Groprinosin with zidovudine leads to an increase in the concentration of zidovudine in the blood plasma and prolongs its half-life. Thus, with the joint use of the drug Groprinosin with zidovudine, it may be necessary to adjust the dose of zidovudine.
special instructions
Groprinosin, like other antivirals, is most effective for acute viral infections if treatment is started at an early stage of the disease (preferably from the first day). Since inosine is excreted from the body in the form of uric acid, it is recommended to periodically monitor the concentration of serum uric acid in case of prolonged use blood and urine. Patients with a significantly increased concentration of uric acid in the body can simultaneously take drugs that lower its concentration. It is necessary to control the concentration of uric acid in the blood serum when administering Groprinosin simultaneously with drugs that increase the concentration of uric acid, or drugs that affect kidney function. Groprinosin should be used with caution in patients with acute liver failure, because the drug is metabolized in the liver. The effect on the ability to drive vehicles and management mehanizmamiVliyanie Groprinosin drug on the psychomotor functions of the body and the ability to drive vehicles and moving machinery has not been studied. When using the drug should take into account the possibility of dizziness and drowsiness.